Corbus Pharmaceuticals Holding Stock Today
| CRBP Stock | USD 6.10 0.35 6.09% |
PerformanceVery Weak
| Odds Of DistressLow
|
Corbus Pharmaceuticals is selling at 6.10 as of the 25th of March 2025; that is 6.09 percent increase since the beginning of the trading day. The stock's last reported lowest price was 5.75. Corbus Pharmaceuticals has less than a 12 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 30th of March 2024 and ending today, the 25th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of November 2014 | Category Healthcare | Classification Health Care |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. The company was incorporated in 2009 and is based in Norwood, Massachusetts. Corbus Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 12.23 M outstanding shares of which 2.44 M shares are currently shorted by private and institutional investors with about 8.52 trading days to cover. More on Corbus Pharmaceuticals Holding
Moving together with Corbus Stock
Moving against Corbus Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Corbus Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO and Director | Yuval Cohen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cannabis (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cannabis, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCorbus Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Corbus Pharmaceuticals' financial leverage. It provides some insight into what part of Corbus Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Corbus Pharmaceuticals Holding (CRBP) is traded on NASDAQ Exchange in USA. It is located in 500 River Ridge Drive, Norwood, MA, United States, 02062 and employs 28 people. Corbus Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 72.9 M. Corbus Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 12.23 M outstanding shares of which 2.44 M shares are currently shorted by private and institutional investors with about 8.52 trading days to cover.
Corbus Pharmaceuticals Holding currently holds about 66.23 M in cash with (41.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53.
Check Corbus Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Corbus Pharmaceuticals is $72.9 Million. The majority of Corbus Pharmaceuticals Holding outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Corbus Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Corbus Pharmaceuticals. Please pay attention to any change in the institutional holdings of Corbus Pharmaceuticals Holding as this could imply that something significant has changed or is about to change at the company. Also note that nearly fourteen thousand six hundred seventy-nine invesors are currently shorting Corbus Pharmaceuticals expressing very little confidence in its future performance.
Check Corbus Ownership Details
Corbus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Armistice Capital, Llc | 2024-12-31 | 236 K | |
| State Street Corp | 2024-12-31 | 228.6 K | |
| Vivo Capital, Llc | 2024-12-31 | 166.8 K | |
| T. Rowe Price Associates, Inc. | 2024-12-31 | 164.7 K | |
| Mirae Asset Global Etfs Holdings Ltd. | 2024-12-31 | 163 K | |
| Ghost Tree Capital, Llc | 2024-09-30 | 160 K | |
| Renaissance Technologies Corp | 2024-12-31 | 139.1 K | |
| Two Sigma Investments Llc | 2024-12-31 | 134.2 K | |
| Northern Trust Corp | 2024-12-31 | 103.3 K | |
| Cormorant Asset Management, Llc | 2024-12-31 | 2.4 M | |
| Orbimed Advisors, Llc | 2024-12-31 | 1.2 M |
Corbus Pharmaceuticals Historical Income Statement
Corbus Stock Against Markets
Corbus Pharmaceuticals Corporate Management
| MD MA | Chief Officer | Profile | |
| Christina Bertsch | Head Resources | Profile | |
| CPA MBA | Chief Officer | Profile | |
| Rachael Brake | Chief Officer | Profile | |
| Lindsey Smith | Head Advocacy | Profile |
Additional Tools for Corbus Stock Analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.